Since HER2-targeted therapies have been approved for use in patients with advanced HER2-positive gastric cancer [47], this illustrates the potential clinical importance of using JAM-A as an alternative route to target HER2 expression in multiple tumor settings. This evidence concerns the gene ERBB2 and neoplasm.